MED23

Across TCGA pan-cancer cohorts, MED23 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MED23 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MED23 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MED23 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, CCRCC, and HNSC are the cancer types where MED23 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.910	0.668	.005	32	view →
CCRCC	DFS	Tertile	II,III,IV	0.750	0.958	.005	26	view →
HNSC	DFS	Median	III,IV	0.906	1.000	.006	16	view →
LUAD	DFS	Quartile	All	0.966	0.785	.017	12	view →
GBM	OS	Tertile	All	0.516	0.301	.022	9	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MED23–LSCC (OS)

Open the LSCC breakdown →